title: Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery.
abstract: OBJECTIVE
  This study was undertaken to develop a new treatment modality that would be able to minimize fibrosis and provide better outcome with glaucoma filtration surgery (GFS).
  
  
  METHODS
  We examined whether co-treatment with mitomycin-C (MMC) and histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) efficiently induces apoptosis on rabbit Tenon's capsule fibroblasts (TCF) in vitro. We further examined the effect of co-treatment with SAHA and MMC on the alteration of IOP and the bleb survival in rabbits following GFS.
  
  
  RESULTS
  Co-treatment of MMC and SAHA efficiently induces apoptosis in TCFs via the up-regulation of p53 and increased phosphorylation of p53 on serine 15 and 392. Also, co-treatment of SAHA and low-dose MMC decreases IOP, prolongs bleb survival, and induces apoptosis of cells under the bleb area following GFS.
  
  
  CONCLUSIONS
  This study shows that a co-treatment of SAHA and MMC could improve the outcome of GFS.
authors: Department of Anatomy and Cell Biology, Dong-A University College of Medicine and Medical Science Research Center, Busan, South Korea.
authors: Tae Hyun
authors: TH
authors: Kim
authors: Sang Woo
authors: SW
authors: Kim
authors: Jung Min
authors: JM
authors: Woo
authors: Jee Hyun
authors: JH
authors: Rho
authors: Dong Jun
authors: DJ
authors: Lee
authors: Jung Min
authors: JM
authors: Park
authors: Woo Jin
authors: WJ
authors: Jeong
authors: Woo Chan
authors: WC
authors: Park
authors: Young Hyun
authors: YH
authors: Yoo
authors: Sae Heun
authors: SH
authors: Rho
mesh_terms: D000477:Alkylating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D053148:Caspase 3 / Q000378:metabolism; D018929:Cell Culture Techniques; D003239:Connective Tissue Cells / Q000187:drug effects; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology*; D005355:Fibrosis / Q000517:prevention & control; D018463:Filtering Surgery; D019084:Fluorescent Antibody Technique, Indirect; D005901:Glaucoma / Q000601:surgery*; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D020287:In Situ Nick-End Labeling; D007429:Intraocular Pressure / Q000187:drug effects; D016685:Mitomycin / Q000494:pharmacology / Q000627:therapeutic use*; D010766:Phosphorylation; D011817:Rabbits; D013524:Surgical Flaps; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D015854:Up-Regulation; D000077337:Vorinostat; D051025:bcl-Associated Death Protein / Q000378:metabolism
chemical_list: D000477:Alkylating Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D016159:Tumor Suppressor Protein p53; D051025:bcl-Associated Death Protein; D016685:Mitomycin; D000077337:Vorinostat; D053148:Caspase 3